2012
Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.
Sinclair N, Abu-Khalaf M, Rizack T, Rosati K, Chung G, Legare R, DiGiovanna M, Fenton M, Bossuyt V, Strenger R, Sakr B, Lannin D, Gass J, Harris L, Sikov W. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. Journal Of Clinical Oncology 2012, 30: 1045-1045. DOI: 10.1200/jco.2012.30.15_suppl.1045.Peer-Reviewed Original ResearchResidual cancer burdenCR/PRTriple-negative breast cancerAnthracycline-based therapyWeekly nab-paclitaxelSerious adverse eventsLonger treatment durationAUC 6Doxorubicin-cyclophosphamideInvasive BRCANeutropenic feverNSABP BWeekly paclitaxelGI bleedNab-paclitaxelAdverse eventsAxillary nodesPartial responseSystemic therapyCancer burdenCohort 2Cohort 1Breast cancerGrade 3BRCA patients
2001
Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer
Tafra L, Verbanac K, Lannin D. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. The American Journal Of Surgery 2001, 182: 312-315. PMID: 11720661, DOI: 10.1016/s0002-9610(01)00718-8.Peer-Reviewed Original ResearchConceptsPrior chemotherapySentinel lymphadenectomyAxillary lymph nodesBreast cancerSentinel nodesPC groupLymph nodesSuspicious axillary lymph nodesSentinel node identification rateOnly exclusion criterionPositive axillary nodesAxillary node dissectionMean tumor sizeStandard of careNon-PC groupPresence of diseaseIsosulfan blueNode dissectionPreoperative chemotherapyAxillary nodesMetastatic diseaseMost patientsPC patientsMulticenter trialTumor sizeMulticenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue Dye
Tafra L, Lannin D, Swanson M, Van Eyk J, Verbanac K, Chua A, Ng P, Edwards M, Halliday B, Henry C, Sommers L, Carman C, Molin M, Yurko J, Perry R, Williams A. Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue Dye. Annals Of Surgery 2001, 233: 51-59. PMID: 11141225, PMCID: PMC1421166, DOI: 10.1097/00000658-200101000-00009.Peer-Reviewed Original ResearchConceptsSentinel node biopsyMulticenter trialTechnetium sulfur colloidNode biopsyIsosulfan blueFalse negative rateOlder patientsSulfur colloidBreast cancerComplete lymph node dissectionInexperienced surgeonsLymph node dissectionMetastatic axillary nodesIsosulfan blue dyeSingle-institution seriesSentinel node localizationBreast cancer metastasisAnalysis of tumorsFalse-negative resultsNode dissectionAxillary nodesIndependent predictorsSentinel nodesPoor success ratePatients